How would you treat a young premenopausal female with triple negative inflammatory breast cancer who progressed on carboplatin/paclitaxel/pembrolizumab (KEYNOTE 522), but didn't receive anthracycline portion and has a positive BRCA2 mutation?

Answer from: Medical Oncologist at Academic Institution

I assume she had surgery already given progression. I would proceed with AC/pembro, and subsequently would continue pembro with the addition of olaparib. Given her BRCA2 mutation, she would not be eligible for Optimice-RD.

Comments

Medical Oncologist at The START Center for Cancer Care
I wish we knew if this person had surgery but why ...

Please select the option that best describes you:

How would you treat a young premenopausal female with triple negative inflammatory breast cancer who progressed on carboplatin/paclitaxel/pembrolizumab (KEYNOTE 522), but didn't receive anthracycline portion and has a positive BRCA2 mutation?

Related Questions